Weight loss with GLP-1 medications typically follows the pattern seen in clinical trials, with more rapid loss in early months that gradually slows
Although they might not provide the immediate boost that prescription stimulants do, some alternatives have safer, longer-term effects as well as fewer cardiovascular side effects, jitteriness, and dependency-like reactions
Adequate protein matters
But the irony is that without nutritional support, the risks and limitations of GLP-1 therapy are significantly higher, making the investment in nutritional support genuinely cost-effective over the longer term
There is increasing recognition of the impact of obesity on workforce health (and as a result, on GDP), which further strengthens the case for healthcare systems investing more to enable additional widespread uptake of GLP-1RAs
Critically, AOD 9604 does not bind the GH receptor with sufficient affinity to activate the JAK2-STAT5 pathway responsible for IGF-1 production
